American journal of therapeutics最新文献

{"title":"Therapeutic Potential of Sodium-Glucose Cotransporter-2 Inhibitors in Nonalcoholic Fatty Liver Disease: A Network Meta-analysis.","authors":"Kannan Sridharan, Gowri Sivaramakrishnan","doi":"10.1097/MJT.0000000000001813","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001813","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":"32 3","pages":"e297-e301"},"PeriodicalIF":2.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143952463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abrocitinib in the Treatment of Drug Reaction With Eosinophilia and Systemic Symptoms.","authors":"ZhiQin Zhang, Juan Liu, Di Wu, WeiLing Sun, ZhiQiang Yin","doi":"10.1097/MJT.0000000000001865","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001865","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":"32 3","pages":"e284-e286"},"PeriodicalIF":2.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mapping the Use of Ketamine in Treatment-Resistant Depression and Other Psychiatric Disorders: A Scoping Review of Practice Patterns, Efficacy, and Patient Demographic Trends.","authors":"Amna M Aslam, Kenneth Shinozuka, Owen Muir, Burton J Tabaac","doi":"10.1097/MJT.0000000000001951","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001951","url":null,"abstract":"<p><strong>Background: </strong>Ketamine has emerged as a novel treatment for psychiatric disorders, particularly treatment-resistant depression (TRD). Although intravenous (IV) ketamine is not approved by the Food and Drug Administration (FDA) for TRD, esketamine, an FDA-approved therapeutic, has contributed to the widespread clinical use of off-label IV ketamine across the United States. This scoping review highlights significant shifts in ketamine therapy, particularly after FDA approval of esketamine, the impact of COVID-19 on treatment accessibility, and increased regulatory scrutiny from the Drug Enforcement Administration (DEA) and FDA.</p><p><strong>Areas of uncertainty: </strong>What are the current practice patterns, patient demographics, and barriers to accessing ketamine for psychiatric disorders, particularly TRD?</p><p><strong>Data sources: </strong>This scoping review focused on provider utilization patterns (including frequency of ketamine administration, provider roles, and treatment settings), preferred administration methods (IV infusions, intramuscular injections, and other routes), and patient characteristics (age, sex, socioeconomic status, and primary psychiatric diagnoses treated). The Web of Science, PubMed, CBM, MEDLINE, Cochrane Library, University Theses, and Embase databases were searched.</p><p><strong>Results: </strong>Two survey-based studies were included. IV administration was the most common method of administration reported in both studies, with alternative methods such as intramuscular and sublingual routes emerging in limited use. Patients receiving ketamine therapy were predominantly middle aged (36-64 years old), with financial barriers identified as a notable obstacle because of limited insurance coverage. Access to ketamine was limited in rural areas, illustrating the need for expanded provider networks. Private clinics exhibited greater flexibility in treatment approaches than hospital settings, which adhered to standardized protocols. The absence of long-term outcome data and variability in treatment protocols emphasize the need for standardized practices and further research.</p><p><strong>Conclusions: </strong>This scoping review highlights the widespread use of ketamine for TRD, but reveals significant variability in practice patterns and accessibility barriers. Findings emphasize the need for standardized protocols, expanded insurance coverage, and further research to optimize the role of ketamine in psychiatric care.</p>","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":"32 3","pages":"e242-e246"},"PeriodicalIF":2.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12061366/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143971457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beta-Adrenergic Blockers for Acute Myocardial Infarction: 50 years of Expert Opinions in Cecil Textbook of Medicine.","authors":"Peter Manu, Gheorghe-Andrei Dan","doi":"10.1097/MJT.0000000000001939","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001939","url":null,"abstract":"<p><strong>Background: </strong>The beta-adrenergic blocker propranolol was synthesized in 1964 by James Black working at the Imperial Chemical Industries in England. The drug did not demonstrate encouraging effects regarding mortality of patients with acute myocardial infarction in clinical trials published in the 1960s in Great Britain and soon thereafter in other countries, but seemed promising after very large studies were conducted in the 1980s in the United States and elsewhere.</p><p><strong>Study question: </strong>What are the milestones of the beta-adrenergic blocker use recommended by experts for the pharmacological management of acute myocardial infarction in the United States?</p><p><strong>Study design: </strong>To determine the changes in the experts' approach to the management of acute myocardial infarction regarding the use of beta-adrenergic blockers as presented in a widely used textbook in the United States.</p><p><strong>Data sources: </strong>The chapters describing the management of acute myocardial infarction in the 15 editions of Cecil Textbook of Medicine updated by recognized experts for clinicians from 1967 through 2020.</p><p><strong>Results: </strong>Beta-adrenergic blockers such as propranolol, timolol, and metoprolol were first mentioned in Cecil Textbook of Medicine in 1985 and recommended unreservedly in Cecil Medicine only since 2000. The record suggests that the expert opinions were shaped by large clinical trials published in the United States in the early 1980s.</p><p><strong>Conclusions: </strong>The decades long delay in the change in the experts' opinion regarding the utility of beta-adrenergic blockers in acute myocardial infarction in the United States is an instance of prudence and well-tempered clinical judgment.</p>","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":"32 3","pages":"e274-e277"},"PeriodicalIF":2.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143973853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meta-Analysis of Dual Antiplatelet Therapy Versus Low-Dose Direct Oral Anticoagulation After Left Atrial Appendage Occlusion.","authors":"Sahib Singh, Kevin Bliden, Udaya S Tantry, Paul A Gurbel, Mohammed Y Kanjwal, Scott W Lundgren","doi":"10.1097/MJT.0000000000001843","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001843","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":"32 3","pages":"e312-e315"},"PeriodicalIF":2.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methicillin-Resistant Staphylococcus aureus Nasal Screening With Polymerase Chain Reaction for Early De-escalation of Empiric Vancomycin in the Treatment of Suspected/Confirmed Respiratory Infection in Critically Ill Patients.","authors":"Amanda Lin, Evelyn Luo, Eric Gottesman, David LeDoux, Patricia Saunders-Hao, Sumeet Jain, Dimitre G Stefanov, Ryan Butzko, Kelvin Wong, Christian Daniel Barrera Maldonado, Pranisha Gautam-Goyal","doi":"10.1097/MJT.0000000000001809","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001809","url":null,"abstract":"<p><strong>Background: </strong>Vancomycin empirically for methicillin-resistant Staphylococcus aureus (MRSA) pneumonia coverage often is prolonged. With high negative predictive value for MRSA pneumonia, we evaluated the efficacy of MRSA nasal screening with polymerase chain reaction for early de-escalation of empiric vancomycin for treatment of respiratory infections in patients admitted to the intensive care units.</p><p><strong>Study question: </strong>The impact of MRSA nasal screening on early de-escalation of vancomycin for respiratory infections.</p><p><strong>Study design: </strong>A retrospective, single-center cohort study was conducted to evaluate the outcomes of vancomycin therapy in patients admitted to the intensive care units with diagnosis of pneumonia before (control group) and after (study group) implementation of MRSA nasal screening.</p><p><strong>Measures and outcomes: </strong>The primary end point was the difference in duration of vancomycin drug therapy in patients with suspected/confirmed pneumonia between the control and study groups. Secondary end points included the number of vancomycin trough levels obtained, discordance between polymerase chain reaction and sputum culture results, and clinical outcomes.</p><p><strong>Results: </strong>In total, 123 patients (control: n = 76; study: n = 47) were included. The median vancomycin duration in the control group and the study group was 73.3 hours (54.3-110.6) and 30.2 hours (20.3-39.7), respectively, P < 0.0001. The control group had 2.73 times (95% CI: 2.15-3.45, P < 0.0001) longer vancomycin duration than the study group. There was a significant difference in the number of trough levels obtained between the 2 groups. The median in the control and study groups were 1 (1-3) and 1 (0-1), respectively, P < 0.0001. There was no difference between groups for length of stay, 30-day readmission for MRSA infection, reinitiation of anti-MRSA therapy for infection, vancomycin-resistant enterococci infection within 30 days, acute kidney injury, and in-hospital all-cause mortality.</p><p><strong>Conclusion: </strong>The implementation of a MRSA nasal screening for critically ill patients treated with vancomycin for pneumonia resulted in a significantly shorter duration of vancomycin treatment without negatively affecting patient outcomes.</p>","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":"32 3","pages":"e217-e222"},"PeriodicalIF":2.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful Treatment of Idiopathic Trachyonychia With Abrocitinib.","authors":"Ruisi Xu, Xiaohong Yu, Li Zhang","doi":"10.1097/MJT.0000000000001941","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001941","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143973850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of SGLT2 Inhibitors and GLP-1 Receptor Agonists on the Risk of Atrial Fibrillation in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.","authors":"Akash Kumar, Mariam Shahabi, Saad Ahmed Waqas, Nisha Kumari, Nimurta Madhwani, Raheel Ahmed, Ram","doi":"10.1097/MJT.0000000000001968","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001968","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143971454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Meta-Analysis Studying the Difference in Response to Trastuzumab-Deruxtecan Based on HER2 Immunohistochemistry Staining in HER2 Low Metastatic Breast Cancer Patients.","authors":"Prashanth Ashok Kumar, Michael Sandhu, Devashish Desai, Metlapalli Sravanthi Venkata, Vishnu Suresh Kumar, Sam Benjamin","doi":"10.1097/MJT.0000000000001894","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001894","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Approaches and Outcomes in Secondary Pulmonary Alveolar Proteinosis Post-hematopoietic Stem Cell Transplantation for Leukemia: A Case Analysis and Review of the Literature.","authors":"Jian-Min Duan, Xiao-Jiu Zha, Jiang-Bo Liu, Hong Zheng, Yu Wu, Li Liu","doi":"10.1097/MJT.0000000000001920","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001920","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143961774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}